Generating AI analysis...
Revenue
$24.07B
++6.66% YoY
EPS (Basic)
$-5.05
-343.96% YoY
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $24.07B | $22.56B | +6.66% |
Cost of Revenue | $6.2B | $5.44B | +13.91% |
Net Income | $-10.23B | $4.33B | -336.01% |
EPS (Basic) | $-5.05 | $2.07 | -343.96% |
EPS (Diluted) | $-5.05 | $2.06 | -345.15% |
R&D Expense | $5.59B | $4.58B | +22.17% |
SG&A Expense | $4.29B | $3.7B | +16.21% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $94.65B | $93.49B | +1.24% |
Current Assets | $26.89B | $28.07B | -4.22% |
Total Liabilities | $77.58B | $61.46B | +26.23% |
Current Liabilities | $23.27B | $20.15B | +15.46% |
Stockholders' Equity | $17.02B | $31.97B | -46.78% |
Cash & Equivalents | $6.29B | $8.37B | -24.83% |
Long-Term Debt | $51.95B | $37.07B | +40.14% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $5.16B | $4.86B | +6.24% |
Investing Cash Flow | $-20.94B | $-539M | -3784.42% |
Financing Cash Flow | $10.62B | $-5.22B | +303.35% |
Dividends Paid | $2.43B | $2.39B | +1.50% |
Share Buybacks | $0 | $1.16B | -100.00% |
D&A | $5.13B | $4.86B | +5.49% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | -42.5% | — | — |
ROE | -60.1% | — | — |
ROA | -10.8% | — | — |
Current Ratio | $1.156 | — | — |
Debt to Equity | $4.559 | — | — |
Other companies in Pharmaceuticals